Generic Name and Formulations:
Methenamine hippurate 1g; tabs; contains tartrazine.
Indications for HIPREX:
Prophylaxis and suppression of recurrent UTIs.
1g twice daily.
<6yrs: not recommended. ≥6yrs: 0.5–1g twice daily.
Renal or severe hepatic insufficiency. Severe dehydration.
Maintain acid urine. Monitor therapy and liver function with repeated urine cultures. Aspirin allergy. Elderly. Pregnancy.
Sulfonamides precipitate with formaldehyde in urine; avoid concomitant use.
Nausea, dysuria, rash, bladder irritation, albuminuria, hematuria, elevated transaminases.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma